Meta Pixel

Landing

Capital Insights
Australia Just Unlocked Access to the World’s Largest R&D Funding Pool. Here’s What It Means for Life Sciences and Deep Tech

Australia has begun formal treaty negotiations to become an associate member of the EU’s Horizon Europe program, the world’s largest single collaborative R&D funding pool. This new status will allow Australian universities and companies to lead projects and access full funding streams on equal terms with EU entities, fundamentally benefiting sectors like life sciences, medical devices, deep tech, and critical minerals.

Capital Insights
From Lick Blocks to Ledger: Why This ‘Boring’ Tech is the New AgTech Gold

In the Australian Outback, 92% of livestock live in extensive grazing systems where consistent nutrition is a logistical nightmare. Mark Peart is changing that by turning the “last mile” of farming into a digital ledger. Learn how DIT AgTech’s uDOSE™ platform is bridging the gap between generational legacy and the global carbon market.

Company Updates
Steve Torso: Founder of Wholesale Investor & CapitalHQ

Steve Torso is the Founder and CEO of Wholesale Investor, Australia’s leading private capital marketplace, and CapitalHQ, the AI-powered Capital Engagement Agent platform transforming how companies raise capital and manage investor relationships. Building Australia’s Private Capital Infrastructure Steve co-founded Wholesale Investor in 2008 with a clear thesis: the gap between companies seeking private capital and […]

Capital Insights
Wholesale Investor: Australia’s Leading Private Capital Marketplace

Since 2008, Wholesale Investor has been connecting qualified investors with high-growth private companies, fund managers, and alternative investment opportunities across Australia and internationally. With a network of over 45,000 investors, the platform is the largest and most established private capital marketplace in Australasia. What is the Wholesale Investor Platform? Wholesale Investor is a business introduction […]

Capital Insights
The Iron Chaperone: Alterity’s High-Stakes Sprint on Brain Iron Redistribution

Multiple System Atrophy (MSA) is a devastating neurological disease with no known cure. Alterity Therapeutics is breaking the “black box” of MSA with ATH434, a first-in-class drug that targets toxic iron accumulation. After successful Phase 2 results, the company is now scaling for a pivotal Phase 3 trial, positioning itself as a frontrunner in a multi-billion dollar orphan drug market.

Join over 45,000+ sophisticated investors

Join Now